GLP-1 for Cats — The Drug Class, the Trials, the Timeline

GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after eating. It signals the pancreas to release insulin, slows gastric emptying, and tells the brain you're full. GLP-1 receptor agonists are drugs that mimic this hormone — Ozempic, Wegovy, Mounjaro, and Zepbound are the human-side blockbusters. As of May 2026, no GLP-1 receptor agonist is FDA-approved for cats. But two pet-specific feline trials are running right now, with results due summer 2026.

Why GLP-1 Drugs Are Being Studied in Cats First

1. Feline obesity is at crisis levels. APOP's vet clinical survey puts US cat overweight/obesity prevalence at 61% — slightly higher than dogs (59%).
2. Cats don't respond well to traditional diets. Restriction-based weight loss in cats often triggers food aggression, redirected behavior, and resistance — the species evolved as solitary hunters, not gradual grazers. A pharmaceutical option fits the species better.
3. Cats lack the breed-pancreatitis risk pattern dogs have. Certain dog breeds (Miniature Schnauzers, Yorkshire Terriers, Cocker Spaniels) carry elevated pancreatitis risk that complicates GLP-1 development for canines. Cats face different risks (hepatic lipidosis with rapid weight loss) but not the breed-specific pancreatitis problem.
4. The commercial market is large. Roughly 50 million US cats in the obesity range, with affluent owners increasingly willing to pay vet-pharma prices for medical interventions.

How GLP-1 Works in Cats vs Humans

GLP-1 receptors exist throughout the cat body — pancreatic beta cells, intestinal epithelium, and CNS — much as they do in humans. Activating these receptors triggers four effects relevant to weight loss:

• •Pancreatic insulin secretion. GLP-1 increases insulin output in response to glucose, improving postprandial glucose control. Particularly relevant for cats at risk of diabetes — about 4× more likely in obese cats than ideal-weight cats.
• •Gastric emptying delay. Food stays in the stomach longer, prolonging satiety signals. Translates to smaller meal sizes and less between-meal hunger.
• •Hypothalamic appetite suppression. GLP-1 signaling reaches CNS appetite centers, reducing the drive to seek food. This is the dominant mechanism for weight loss effect size.
• •Glucagon suppression. Reduces hepatic glucose output, supporting glucose stability.

The cross-species translation is imperfect. Human GLP-1 trials show 5-15% body weight reduction over 6-12 months. Whether feline trials replicate this depends on receptor density differences, dosing, and the specific molecule used. The two active trials use different molecules — Okava's exenatide implant and Akston's novel Fc-fusion — so we may get two different efficacy signals from the readouts.

The Two Active Trials

Detail on each: MEOW-1 trial breakdown · Akston AKS-562c + Cornell trial · Okava pipeline tracker

Why You Can't Get Human GLP-1 Drugs for Your Cat

Veterinarians will not legally prescribe Ozempic, Wegovy, Mounjaro, or any other human-approved GLP-1 to cats. Three reasons:

1. Species-specific dosing has never been studied. Human dosing scales by body weight, but GLP-1 receptor density and incretin response differ between species. A 'safe' human dose could be sub-therapeutic or unsafe in a cat.
2. Hepatic lipidosis risk with rapid weight loss. Cats who lose weight too fast develop fatty liver disease, often fatal. GLP-1-driven appetite suppression could trigger weight loss faster than the cat's liver can adapt.
3. FDA veterinary compounding restrictions. April 2026 FDA-CVM guidance limits compounding of human drugs for off-label species use without specific clinical justification. 'My cat is overweight' is not a clinical justification when food therapy is the standard of care.

What to Watch in the Readouts

When MEOW-1 (summer 2026) and the Cornell AKS-562c trial (Q2-Q3 2026) report results, the field will read along five axes:

• •Body weight change — meaningful efficacy clusters in the 4-10% range over 3 months. Above 10% is a strong signal.
• •Body Condition Score (BCS) shift — vets care about the 9-point scale, not raw weight. Target: average drop from BCS 7 to BCS 5-6.
• •Adverse events — particularly hepatic enzyme elevations (ALT, ALP). Vomiting and decreased appetite are expected; severity matters.
• •Owner compliance — for Akston's weekly injection, dropouts attributable to handling difficulty are a commercial signal.
• •Cohort expansion decisions — Akston has option to expand 70→140 cats. Expansion is a confidence signal; non-expansion could mean the answer was clear either way.